| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(5): 363-385.
|
| [3] |
Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest [J]. J Clin Oncol, 2007, 25(13): 1670-1676.
|
| [4] |
Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial [J]. JAMA, 2017, 317(23): 2392-2401.
|
| [5] |
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J]. Lancet, 2013, 381(9863): 303-312.
|
| [6] |
Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer [J]. N Engl J Med, 2015, 372(20): 1909-1919.
|
| [7] |
Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial [J]. JAMA, 2018, 319(24): 2486-2496.
|
| [8] |
Ettrich TJ, Seufferlein T. Regorafenib [J]. Recent Results Cancer Res, 2018, 211: 45-56.
|
| [9] |
Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2015, 16(6): 619-629.
|
| [10] |
Nakashima M, Ide K, Kawakami K. Comparison of standard initial dose and reduced initial dose regorafenib for colorectal cancer patients: a retrospective cohort study [J]. Target Oncol, 2019, 14(3): 295-306.
|
| [11] |
Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phaseIII Trial of trifluridine/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study [J]. J Clin Oncol, 2018, 36(4): 350-358.
|
| [12] |
Deng Y, Li X. Fruquintinib and its use in the treatment of metastatic colorectal cancer [J]. Future Oncol, 2019, 15(22): 2571-2576.
|
| [13] |
Shirley M. Fruquintinib: first global approval [J]. Drugs, 2018, 78(16): 1757-1761.
|
| [14] |
Dasari A, Sobrero A, Yao J, et al. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer [J]. Future Oncol, 2021, 17(24): 3151-3162.
|
| [15] |
Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1 [J]. Gene, 2018, 654: 77-86.
|
| [16] |
Chi Y, Shu Y, Ba Y, et al. Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase Ⅲ trial (ALTER0703) [J]. Oncologist, 2021, 26(10): e1693-e1703.
|
| [17] |
Jonker DJ, O'callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer [J]. N Engl J Med, 2007, 357(20): 2040-2048.
|
| [18] |
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004, 351(4): 337-345.
|
| [19] |
Cremolini C, Rossini D, Dell'aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial [J]. JAMA Oncol, 2019, 5(3): 343-350.
|
| [20] |
Suenaga M, Mizunuma N, Matsusaka S, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study [J]. Drug Des Devel Ther, 2015, 9: 3099-3108.
|
| [21] |
Costa T, Nuñez J, Felismino T, et al. REOX: Evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study [J]. Clin Colorectal Cancer, 2017, 16(4): 316-323.
|
| [22] |
Yang Q, Huang Y, Jiang Z, et al. Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer [J]. Onco Targets Ther, 2018, 11: 2467-2473.
|
| [23] |
Briani C, Argyriou AA, Izquierdo C, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study [J]. J Peripher Nerv Syst, 2014, 19(4): 299-306.
|
| [24] |
Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer [J]. J Natl Cancer Inst, 2017, 109(12).
|
| [25] |
Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3 256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials [J]. J Pathol, 2016, 238(4): 562-570.
|
| [26] |
Javle M, Borad MJ, Azad NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study [J]. Lancet Oncol, 2021, 22(9): 1290-1300.
|
| [27] |
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2016, 17(6): 738-746.
|
| [28] |
Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2021, 22(6): 779-789.
|
| [29] |
Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors [J]. Cancer Cell, 2020, 37(4): 543-550.
|
| [30] |
Ou SI, Jänne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1) [J]. J Clin Oncol, 2022, 40(23): 2530-2538.
|
| [31] |
Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer [J]. Br J Cancer, 2011, 104(5): 856-862.
|
| [32] |
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer [J]. N Engl J Med, 2019, 381(17): 1632-1643.
|
| [33] |
Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 372(26): 2509-2520.
|
| [34] |
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer [J]. J Clin Oncol, 2018, 36(8): 773-779.
|
| [35] |
Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) [J]. J Clin Oncol, 2020, 38(18): 2053-2061.
|
| [36] |
Yoshida Y, Yamada T, Kamiyama H, et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study [J]. Int J Clin Oncol, 2021, 26(1): 111-117.
|
| [37] |
Van Cutsem E, Danielewicz I, Saunders MP, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study [J]. Ann Oncol, 2020, 31(9): 1160-1168.
|
| [38] |
Shitara K, Yamanaka T, Denda T, et al. REVERCE: a randomized phase Ⅱ study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients [J]. Ann Oncol, 2019, 30(2): 259-265.
|
| [39] |
Tai CC, Chen WS, Jiang JK, et al. Comparing late-line treatment sequence of regorafenib and reduced-intensity FOLFOXIRI for Refractory metastatic colorectal cancer[J]. Am J Clin Oncol, 2020, 43(1): 28-34.
|